A debate rages in the tech community over whether IBM's Watson computing system is all hype, or the source of real and potential advances in the science of artificial intelligence. Venture Capitalist Chamath Palihapitiya, for instance, has called Watson a "joke" that is the product of IBM's PR operations rather than serious AI science.
MIT's Tech Review, however, recently argued Watson "will be a leader in applying AI to health care's woes," and that if it hasn't achieved hoped-for breakthroughs yet, it's only because "it needs certain types of data to be 'trained,'" and that this data has been difficult to access—a problem that all AI-intensive firms face, not just IBM.
Wall Street is skeptical: Just 5 analysts of 21 tracked by Money.net have a buy rating on IBM stock, while Jefferies analyst James Kisner cut his price target for the company again Tuesday, from $135 to $125, based on his skepticism of Watson. The stock was trading at $153.81 as of publication.